Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Phase II dose-to-rash study of Tarceva

Nov. 12, 2003

Eligard products receive Canadian approval

Nov. 12, 2003

Hybrigenics and Servier sign new drug discovery agreements

Nov. 11, 2003

New ErbB kinase inhibitors, their preparation and use revealed in AstraZeneca patent

Nov. 11, 2003

BMS researchers present new protein kinase inhibitors for proliferative and inflammatory disorders

Nov. 11, 2003

Xcytrin evaluated in combination with Rituxan and Zevalin

Nov. 10, 2003

New EGFR inhibitors discovered at Boehringer Ingelheim

Nov. 10, 2003

Good efficacy and safety profile reported for arzoxifene in hormone-sensitive breast cancer

Nov. 10, 2003

Troxacitabine safety and efficacy in CML-BP

Nov. 7, 2003

Oral topoisomerase I inhibitor added to Novartis pipeline

Nov. 7, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...